Original editorial analysis: pricing math, regulatory explainers, clinical evidence, transparency analysis, and honest tradeoffs in the compounded semaglutide telehealth market. 20 articles, monthly updates.
What the STEP trials found — 14.9% mean weight loss in STEP 1, 15.2% sustained at two years — and how to turn efficacy into cost-per-result. With charts.
Side effects by trial frequency (nausea ~44% vs 18% placebo), why they cluster at dose escalation, the boxed thyroid warning, and a week-by-week plan.
The mechanism behind the STEP-trial weight loss: appetite, gastric emptying, glucose control — and why it doses once a week. Oral vs injectable too.
Two-thirds of lost weight returns within a year of stopping (STEP 1 extension). The maintenance economics and why the plan you pick matters. Charts.
SURMOUNT-5 efficacy (13.7% vs 20.2%), compounded pricing ($145 vs $186/mo), and a cost-per-result framework to decide which fits your goals.
A 20% reduction in heart attacks and strokes in SELECT (17,604 patients). Blood pressure, lipids, and why the cardiac data changes the insurance argument.
Two legal compounding categories behind one word. What separates them, why the resolved shortage narrowed the rules, and a 10-minute verification checklist.
Different regulatory categories, not the same drug at different prices. A category breakdown, the annual-cost chart, and the insurance path people skip.
Why compounded pricing is national but access is local, telehealth rules by state, and the hidden HSA/FSA tax dimension that changes your real cost.
The full dose ladder (0.25–2.4 mg), how long titration takes, and the chart showing why flat-rate pricing matters more with every escalation.
The FLOW trial (NEJM 2024) found semaglutide reduced major kidney and cardiovascular events by about 24% in type 2 diabetes with chronic kidney disease. What it means — and its limits.
How oral semaglutide (including 25 mg, OASIS-4) compares with injectable semaglutide 2.4 mg (STEP 1) for weight loss in 2026, and what it means for telehealth patients.
What the STEP-4 trial shows about weight regain after stopping semaglutide, why obesity is treated as a chronic condition, and what it means for long-term cost planning.
The standard semaglutide titration schedule from 0.25 mg to 2.4 mg, why doses step up gradually, the dose-response from trials, and why flat-rate pricing matters as your dose rises.
Whether semaglutide causes muscle (lean mass) loss, what trial body-composition data show, and how protein intake and resistance training help preserve muscle during weight loss.
Whether compounded semaglutide works like Wegovy, what the same-active-ingredient argument does and doesn't prove, base vs salt forms, and the FDA-approval difference.
What compounded semaglutide really costs per month in 2026 — starter vs maintenance, membership and shipping fees, and how to find the true monthly cost.
How to find the most affordable compounded semaglutide in 2026 by comparing true monthly cost — not the advertised starter price.
A step-by-step 2026 checklist for buying compounded semaglutide online safely — verify the prescriber, the pharmacy, the price, and the terms.
“Compounded semaglutide near me” almost always means telehealth access in your state. Here's how state-licensed prescribing and pharmacy shipping work.
Semaglutide vs tirzepatide in 2026: how the two GLP-1 options compare on weight-loss evidence, cost, and access.
Why $99 compounded semaglutide offers are usually teaser pricing — and how to find the true monthly cost.
503A vs 503B compounding pharmacies for semaglutide: what the distinction means for sourcing, oversight, and patient safety in 2026.
Compounded semaglutide safety in 2026: common side effects, who should avoid it, and how to reduce risk through proper oversight.
Semaglutide cost without insurance in 2026: how cash-pay compounded programs compare to brand pricing, and how to find the lowest true monthly cost.
A patient-friendly explainer of the 2026 FDA compounding landscape for semaglutide: shortage resolution, the 503B bulks list proposal, and what it means for access.
Standard semaglutide titration takes 16-20 weeks to reach maintenance dose. We work the math on a $99 first-month offer vs flat-rate, and why the 12-month delta is typically $900-$1,800.
503A and 503B compounding pathways operate under different federal frameworks. We explain what each means for sterility QC, batch testing, prescription requirements, and your safety profile.
Six weeks after the FDA's 2026 compounding framework targeting compounded GLP-1 medications, what's actually changed for patients. The framework, the enforcement targets, and what compliant providers look like.
Of 25 directory providers, only one publicly discloses all six named partner pharmacies pre-purchase. Why this single transparency item carries 22% of our six-pillar score.
STEP-1 showed ~15% weight loss at 68 weeks with brand-name semaglutide 2.4 mg. SELECT showed 20% cardiovascular event reduction. What these trials mean for compounded semaglutide outcomes.
Brand-name Wegovy/Ozempic is FDA-approved with extensive clinical-trial backing. Compounded semaglutide is not. We walk through the patient-by-patient decision logic.
Pharmacy disclosure, dose-tier pricing, medical director credentials, included support, cancellation terms. The five-minute pre-signup interview that protects you from the worst telehealth tier.
Many telehealth providers list 'patient support included' without specifying what's bundled. We define what included support should cover, and how Care360 compares.
Most semaglutide telehealth comparison content stops at the first-month price. We show the full 12-month math on NexLife, Henry Meds, Mochi, Hims, and Ro Body.
If compounded is so much cheaper, why isn't everyone on it? The honest tradeoffs — not FDA-approved, formula variability, regulatory uncertainty — and how to evaluate whether they apply to you.
Compounded semaglutide is not an FDA-approved drug product. It is a compounded preparation made by state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities under federal compounding law (21 USC §353a/§353b). Not identical or generic-equivalent to brand-name Wegovy or Ozempic. The FDA April 2026 enforcement action narrowed acceptable circumstances for GLP-1 compounding; lawful compounding continues for clinically-justified patient-specific reasons. This page is editorial and not medical advice.